^
    2d
    GEM-TECTAL: Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, PETHEMA Foundation | Trial primary completion date: Mar 2025 --> Mar 2026
    Trial primary completion date
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    6d
    Central nervous system involvement in multiple myeloma as a first manifestation of relapse and potential diagnostic pitfall. (PubMed, Cytometry B Clin Cytom)
    Two patients presented interference in FCM analysis, supporting the penetration of daratumumab into the CSF...Flow-cytometry panels need to be optimized for plasma-cell detection, especially among patients treated with anti-CD38 antibodies. Identifying patients at risk remains crucial, but prognostic biomarkers such as IL-6 still require validation.
    Journal • IO biomarker
    |
    IL6 (Interleukin 6) • IL10 (Interleukin 10)
    |
    Darzalex (daratumumab)
    8d
    A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    lenalidomide • Darzalex (daratumumab) • carfilzomib • dexamethasone
    9d
    IMROZ: A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (clinicaltrials.gov)
    P3, N=475, Active, not recruiting, Sanofi | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial primary completion date
    |
    lenalidomide • bortezomib • dexamethasone • Sarclisa (isatuximab-irfc) • dexamethasone injection
    13d
    ISASOCUT: Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma (clinicaltrials.gov)
    P=N/A, N=74, Active, not recruiting, Poitiers University Hospital | Trial primary completion date: Jul 2026 --> Mar 2026
    Trial primary completion date
    |
    lenalidomide • bortezomib • dexamethasone • isatuximab subcutaneous (SAR650984 SC)
    14d
    IZALCO: A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=118, Active, not recruiting, Sanofi | N=55 --> 118
    Enrollment change
    |
    carfilzomib • dexamethasone • dexamethasone injection • isatuximab subcutaneous (SAR650984 SC)
    14d
    Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) (clinicaltrials.gov)
    P1, N=200, Recruiting, Ichnos Sciences SA | N=85 --> 200
    Enrollment change • First-in-human
    |
    ABBV-2001
    15d
    PRIDE: Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma (clinicaltrials.gov)
    P1/2, N=16, Active, not recruiting, West Virginia University | Trial completion date: Feb 2026 --> Dec 2026 | Trial primary completion date: Feb 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    temozolomide • Darzalex (daratumumab)
    16d
    TRANSCEND LTE: A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) (clinicaltrials.gov)
    P3, N=120, Enrolling by invitation, Biogen | Not yet recruiting --> Enrolling by invitation
    Enrollment open
    |
    felzartamab (MOR202)
    16d
    ICING: Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy (clinicaltrials.gov)
    P2, N=37, Completed, Won Seog Kim | Recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Libtayo (cemiplimab-rwlc) • Sarclisa (isatuximab-irfc)
    23d
    Monocyte-mediated metabolic rewiring via CD31-CD38 interactions promotes growth and drug-resistance in multiple myeloma. (PubMed, Hemasphere)
    Daratumumab-mediated disruption of mitochondrial transfer reduced the mitochondrial content in MM cells, prevented the boost in OXPHOS, significantly impaired MM cell growth and migration, and mitigated drug-resistance. In conclusion, we reveal a crucial metabolic interplay between monocytes and MM cells within the BM microenvironment that promotes tumor growth and induces therapy resistance, providing the rationale for treatment strategies that combine targeting tumor metabolism with existing anti-MM agents.
    Journal • IO biomarker
    |
    CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    Darzalex (daratumumab)
    23d
    A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1/2, N=159, Not yet recruiting, Sinocelltech Ltd.
    New P1/2 trial